<p>± Standard deviation.</p><p>Post treatment residual mass in 33 SCC sites (primary plus nodal): mean DCE and volumes (and % change when compared to pre-treatment), and clinical parameters for SC residual masses and SF residual masses, based on a minimum of 2 year clinical follow-up.</p
<p>Based on independent <i>t</i>-tests, average non-enhanced tumor fractions were significantly diff...
<p>Tumor weight derived from MR images before and two weeks after initiation of therapy, and, by nec...
Difference of the means ± standard deviations and confidence interval in the cortical and marrow com...
<p>± Standard deviation.</p><p>Pre-treatment mean DCE, volumes and clinical parameters in 83 SCC sit...
<p>± Standard deviation.</p><p>Pre-treatment mean DCE parameters in 43 primary sites and 40 nodal si...
<p>SC residual masses showed significantly lower AUGC than SF residual masses.</p
<p>Note: VOL<sub>B</sub>: baseline tumor volume; VOL<sub>F</sub>: follow-up tumor volume, ΔVOL: tumo...
Percentage change in tumour volume between the 6 month, 12 month, 24 month and last follow-up CT rel...
Purpose: Guidelines for management of postchemo-therapy residual mass in patients with advanced semi...
<p>Mean (± standard deviation) coordinates and stimulation parameters of 29 patients with GPm DBS an...
Background and Purpose It is important to identify patients with head and neck squamous cell carcino...
<p>Note: ADC<sub>B</sub>: baseline tumor ADC; ADC<sub>F</sub>: follow-up tumor ADC, ΔADC: tumor ADC ...
<p>Tumor sizes before and after neoadjuvant chemotherapy with the percent of SCC-ag decease.</p
<p>Percentage changes in tumor MRI measurements after treatment compared with pre-treatment.</p
Baseline characteristics of the study population at the time of 1st TACE due to recurrent HCC after ...
<p>Based on independent <i>t</i>-tests, average non-enhanced tumor fractions were significantly diff...
<p>Tumor weight derived from MR images before and two weeks after initiation of therapy, and, by nec...
Difference of the means ± standard deviations and confidence interval in the cortical and marrow com...
<p>± Standard deviation.</p><p>Pre-treatment mean DCE, volumes and clinical parameters in 83 SCC sit...
<p>± Standard deviation.</p><p>Pre-treatment mean DCE parameters in 43 primary sites and 40 nodal si...
<p>SC residual masses showed significantly lower AUGC than SF residual masses.</p
<p>Note: VOL<sub>B</sub>: baseline tumor volume; VOL<sub>F</sub>: follow-up tumor volume, ΔVOL: tumo...
Percentage change in tumour volume between the 6 month, 12 month, 24 month and last follow-up CT rel...
Purpose: Guidelines for management of postchemo-therapy residual mass in patients with advanced semi...
<p>Mean (± standard deviation) coordinates and stimulation parameters of 29 patients with GPm DBS an...
Background and Purpose It is important to identify patients with head and neck squamous cell carcino...
<p>Note: ADC<sub>B</sub>: baseline tumor ADC; ADC<sub>F</sub>: follow-up tumor ADC, ΔADC: tumor ADC ...
<p>Tumor sizes before and after neoadjuvant chemotherapy with the percent of SCC-ag decease.</p
<p>Percentage changes in tumor MRI measurements after treatment compared with pre-treatment.</p
Baseline characteristics of the study population at the time of 1st TACE due to recurrent HCC after ...
<p>Based on independent <i>t</i>-tests, average non-enhanced tumor fractions were significantly diff...
<p>Tumor weight derived from MR images before and two weeks after initiation of therapy, and, by nec...
Difference of the means ± standard deviations and confidence interval in the cortical and marrow com...